The prevention and regression of atherosclerotic plaques: emerging treatments

References

• RogerVLGoALLloyd-JonesDMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeExecutive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart AssociationCirculation201212518819722215894
   PubMed Web of Science ®Google Scholar
• HeidenreichPATrogdonJGKhavjouOAAmerican Heart Association Advocacy Coordinating CommitteeStroke CouncilCouncil on Cardiovascular Radiology and InterventionCouncil on Clinical CardiologyCouncil on Epidemiology and PreventionCouncil on ArteriosclerosisThrombosis and Vascular BiologyCouncil on CardiopulmonaryCritical CarePerioperative and ResuscitationCouncil on Cardiovascular NursingCouncil on the Kidney in Cardiovascular DiseaseCouncil on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes ResearchForecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationCirculation2011123893394421262990
   PubMed Web of Science ®Google Scholar
• MallikaVGoswamiBRajappaMAtherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspectiveAngiology200758551352218024933
   PubMed Web of Science ®Google Scholar
• FlemingRMThe effect of high-, moderate-, and low-fat diets on weight loss and cardiovascular disease risk factorsPrev Cardiol20025310118
   Google Scholar
• DeanfieldJEHalcoxJPRabelinkTJEndothelial function and dysfunction: testing and clinical relevanceCirculation2007115101285129517353456
   PubMed Web of Science ®Google Scholar
• TousoulisDKampoliAMTentolourisCPapageorgiouNStefanadisCThe role of nitric oxide on endothelial functionCurr Vasc Pharmacol201210141822112350
   PubMed Web of Science ®Google Scholar
• ShahPKMolecular mechanisms of plaque instabilityCurr Opin Lipidol200718549249917885418
   PubMed Web of Science ®Google Scholar
• CalabresiLSimonelliSGomaraschiMFranceschiniGGenetic lecithin:cholesterol acyltransferase deficiency and cardiovascular diseaseAtherosclerosis2012222229930622189200
   PubMed Web of Science ®Google Scholar
• SanzJMorenoPRFusterVThe year in atherothrombosisJ Am Coll Cardiol200953151326133719358949
   PubMed Web of Science ®Google Scholar
• FalkEPathogenesis of atherosclerosisJ Am Coll Cardiol200647Suppl 8C7C1216631513
   PubMed Web of Science ®Google Scholar
• StoneGWMaeharaALanskyAJPROSPECT InvestigatorsA prospective natural-history study of coronary atherosclerosisN Engl J Med2011364322623521247313
   PubMed Web of Science ®Google Scholar
• O’LearyDHPolakJFKronmalRAManolioTABurkeGLWolfsonSKJrCarotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research GroupN Engl J Med1999340114229878640
   PubMed Web of Science ®Google Scholar
• KaveyREDanielsSRLauerRMAtkinsDLHaymanLLTaubertKAmerican Heart AssociationAmerican Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhoodCirculation2003107111562156612654618
   PubMed Web of Science ®Google Scholar
• GreenlandPAlpertJSBellerGAAmerican College of Cardiology FoundationAmerican Heart Association2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20105625e50e10321144964
   PubMed Web of Science ®Google Scholar
• GiddingSSLichtensteinAHFaithMSImplementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure ResearchCirculation200911981161117519255356
   PubMed Web of Science ®Google Scholar
• ZebIBudoffMJMESA: The NIH-sponsored study that validates atherosclerosis imaging for primary preventionCurr Atheroscler Rep201113535335821785969
   PubMed Web of Science ®Google Scholar
• NaghaviMFalkEHechtHSSHAPE Task Force. From vulnerable plaque to vulnerable patient – Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force reportAm J Cardiol2006982A2H15H
   PubMed Web of Science ®Google Scholar
• Aguilar-SheaALGallardo-MayoCGarrido-ElustondoSCalvo-ManuelEZamorano-GómezJLCarotid intima-media thickness as a screening tool in cardiovascular primary preventionEur J Clin Invest201141552152621155766
   PubMed Web of Science ®Google Scholar
• HechtHSThe role of atherosclerosis imaging in redefining normal and abnormal cholesterol values, and risk reduction in primary prevention statin trialsCurr Atheroscler Rep201113542243021792639
   PubMed Web of Science ®Google Scholar
• LenfantFTrémollièresFGourdyPArnalJFTiming of the vascular actions of estrogens in experimental and human studies: why protective early, and not when delayed?Maturitas201168216517321167666
   PubMed Web of Science ®Google Scholar
• DenisetJFPierceGNPossibilities for therapeutic interventions in disrupting Chlamydophila pneumoniae involvement in atherosclerosisFundam Clin Pharmacol201024560761720653790
   PubMed Web of Science ®Google Scholar
• PashkowFJOxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?Int J Inflam20112011514623
   Google Scholar
• ReisJPLoriaCMSteffenLMCoffee, decaffeinated coffee, caffeine, and tea consumption in young adulthood and atherosclerosis later in life: the CARDIA studyArterioscler Thromb Vasc Biol201030102059206620616310
   PubMed Web of Science ®Google Scholar
• MuntendamPMcCallCSanzJFalkEFusterVHigh-Risk Plaque InitiativeThe BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease – study design and objectivesAm Heart J20101601495720598972
   PubMed Web of Science ®Google Scholar
• DauchetLAmouyelPDallongevilleJFruits, vegetables and coronary heart diseaseNat Rev Cardiol20096959960819652655
   PubMed Web of Science ®Google Scholar
• JableckaABogdańskiPBalcerNCieślewiczASkołudaAMusialikKThe effect of oral L-arginine supplementation on fasting glucose, HbA1c, nitric oxide and total antioxidant status in diabetic patients with atherosclerotic peripheral arterial disease of lower extremitiesEur Rev Med Pharmacol Sci201216334235022530351
   PubMed Web of Science ®Google Scholar
• SzostakJLaurantPThe forgotten face of regular physical exercise: a “natural” anti-atherogenic activityClin Sci (Lond)201112139110621729002
   PubMed Web of Science ®Google Scholar
• AhmedHMBlahaMJNasirKRiveraJJBlumenthalRSEffects of physical activity on cardiovascular diseaseAm J Cardiol2012109228829522011559
   PubMed Web of Science ®Google Scholar
• FordMAAllisonTGLermanANew approaches to the concept of primary prevention of atherosclerosisCurr Treat Options Cardiovasc Med2008101738218325309
   PubMedGoogle Scholar
• SmithSCJrBenjaminEJBonowROAHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology FoundationCirculation20111129124222458247322052934
   PubMed Web of Science ®Google Scholar
• SmithSCJrBenjaminEJBonowROWorld Heart Federation and the Preventive Cardiovascular Nurses AssociationAHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology FoundationCirculation2011124222458247322052934
   PubMed Web of Science ®Google Scholar
• LichtmanJHBiggerJTJrBlumenthalJAAmerican Heart Association Prevention Committee of the Council on Cardiovascular NursingAmerican Heart Association Council on Clinical CardiologyAmerican Heart Association Council on Epidemiology and PreventionAmerican Heart Association Interdisciplinary Council on Quality of Care and Outcomes ResearchAmerican Psychiatric AssociationDepression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric AssociationCirculation2008118171768177518824640
   PubMed Web of Science ®Google Scholar
• LeonASFranklinBACostaFAmerican Heart AssociationCouncil on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention)Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)American association of Cardiovascular and Pulmonary RehabilitationCardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary RehabilitationCirculation2005111336937615668354
   PubMed Web of Science ®Google Scholar
• BrottTGHalperinJLAbbaraSAmerican College of Cardiology FoundationAmerican Stroke AssociationAmerican Association of Neurological SurgeonsAmerican College of RadiologyAmerican Society of NeuroradiologyCongress of Neurological SurgeonsSociety of Atherosclerosis Imaging and PreventionSociety for Cardiovascular Angiography and InterventionsSociety of Interventional RadiologySociety of NeuroInterventional SurgerySociety for Vascular MedicineSociety for Vascular Surgery2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular SurgeryCirculation2011124448953221282505
   PubMed Web of Science ®Google Scholar
• WallentinLBeckerRCBudajAPLATO InvestigatorsFreijAThorsénMTicagrelor versus clopidogrel in patients with acute coronary syndromesN Engl J Med2009361111045105719717846
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEMcCabeCHTRITON–TIMI 38 InvestigatorsPrasugrel versus clopidogrel in patients with acute coronary syndromesN Engl J Med2007357202001201517982182
   PubMed Web of Science ®Google Scholar
• GersteinHCRatnerRECannonCPAPPROACH Study GroupEffect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trialCirculation2010121101176118720194881
   PubMed Web of Science ®Google Scholar
• García-GarcíaHMGargSBrugalettaSAPPROACH study groupEvaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression by Rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history)Int J Cardiovasc Imaging201228345546521359834
   PubMed Web of Science ®Google Scholar
• FrancisAAPierceGNAn integrated approach for the mechanisms responsible for atherosclerotic plaque regressionExp Clin Cardiol2011163778622065938
   PubMedGoogle Scholar
• BediUSinghMSinghPMolnarJKhoslaSAroraREffects of statins on progression of coronary artery disease as measured by intravascular ultrasoundJ Clin Hypertens (Greenwich)201113749249621762362
   PubMed Web of Science ®Google Scholar
• HanSHChungWJKangWCRosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: Comparative analysis with rosuvastatin alone by intravascular ultrasoundInt J Cardiol2012158221722421295363
   PubMed Web of Science ®Google Scholar
• TakayamaTHiroTYamagishiMCOSMOS InvestigatorsEffect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)Circ J200973112110211719801853
   PubMed Web of Science ®Google Scholar
• HibiKKimuraTKimuraKJAPAN-ACS InvestigatorsClinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trialAtherosclerosis2011219274374921899843
   PubMed Web of Science ®Google Scholar
• AraiHHiroTKimuraTJAPAN-ACSInvestigators. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome – sub-analysis of JAPAN-ACS studyJ Atheroscler Thromb201017101096110720675955
   PubMed Web of Science ®Google Scholar
• HongYJJeongMHHachinoheDComparison of Effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosisCirc J201175239840621157106
   PubMed Web of Science ®Google Scholar
• TaniSNagaoKAnazawaTRelation of change in apolipoprotein B/apolipoprotein A–I ratio to coronary plaque regression after Pravastatin treatment in patients with coronary artery diseaseAm J Cardiol2010105214414820102908
   PubMed Web of Science ®Google Scholar
• KawaharaTNishikawaMFurusawaTInazuTSuzukiGEffect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imagingJ Atheroscler Thromb201118538439521282896
   PubMed Web of Science ®Google Scholar
• KoYGKimBKLeeBKSECURE Investigators. Study design and rationale of “Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)” study: a double-blind randomised controlled multicenter clinical trialTrials2011121021226953
   PubMed Web of Science ®Google Scholar
• KovarnikTMintzGSSkalickaHVirtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN studyCirc J201276117618322076422
   PubMed Web of Science ®Google Scholar
• MigrinoRQBowersMHarmannLProstRLaDisaJFJrCarotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thicknessJ Cardiovasc Magn Reson2011133721812992
   PubMed Web of Science ®Google Scholar
• NichollsSJBallantyneCMBarterPJEffect of two intensive statin regimens on progression of coronary diseaseN Engl J Med2011365222078208722085316
   PubMed Web of Science ®Google Scholar
• NichollsSJTuzcuEMSipahiIStatins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosisJAMA2007297549950817284700
   PubMed Web of Science ®Google Scholar
• YangHBZhaoXYZhangJYDuYYWangXFPioglitazone induces regression and stabilization of coronary atherosclerotic plaques in patients with impaired glucose toleranceDiabet Med201229335936521950726
   PubMed Web of Science ®Google Scholar
• NakayamaTKomiyamaNYokoyamaMPioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasoundInt J Cardiol2010138215716518817993
   PubMed Web of Science ®Google Scholar
• ClementiFDi LuozzoMMangoRRegression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysisJ Cardiovasc Med (Hagerstown)200910323123719262209
   PubMed Web of Science ®Google Scholar
• KadoglouNPSailerNMoumtzouoglouAKapelouzouAGerasimidisTLiapisCDAggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilizationJ Vasc Surg201051111412119837545
   PubMed Web of Science ®Google Scholar
• ShaiISpenceJDSchwarzfuchsDDIRECT GroupDietary intervention to reverse carotid atherosclerosisCirculation2010121101200120820194883
   PubMed Web of Science ®Google Scholar
• GodinBSakamotoJHSerdaREGrattoniABouamraniAFerrariMEmerging applications of nanomedicine for therapy and diagnosis of cardiovascular diseasesTrends Pharmacol Sci201031519920520172613
   PubMed Web of Science ®Google Scholar
• LobattoMEFusterVFayadZAMulderWJPerspectives and opportunities for nanomedicine in the management of atherosclerosisNat Rev Drug Discov2011101183585222015921
   PubMed Web of Science ®Google Scholar
• O’NeilCPvan der VliesAJVellutoDExtracellular matrix binding mixed micelles for drug delivery applicationsJ Control Release2009137214615119332089
   PubMed Web of Science ®Google Scholar
• ChanJMZhangLTongRSpatiotemporal controlled delivery of nanoparticles to injured vasculatureProc Natl Acad Sci U S A201010752213221820133865
   PubMed Web of Science ®Google Scholar
• GordonTCastelliWPHjortlandMCKannelWBDawberTRHigh density lipoprotein as a protective factor against coronary heart disease. The Framingham StudyAm J Med1977625707714193398
   PubMed Web of Science ®Google Scholar
• SharrettARBallantyneCMCoadySACoronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A–I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) StudyCirculation2001104101108111311535564
   PubMed Web of Science ®Google Scholar
• ForresterJSShahPKEmerging strategies for increasing high-density lipoproteinAm J Cardiol200698111542154917126667
   PubMed Web of Science ®Google Scholar
• FayadZAManiVWoodwardMdal-PLAQUE InvestigatorsSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet201137898021547155921908036
   PubMed Web of Science ®Google Scholar
• BoettcherMFHeinigRSchmeckCSingle dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer proteinBr J Clin Pharmacol201273221021821838789
   PubMed Web of Science ®Google Scholar
• GutsteinDEKrishnaRJohnsDAnacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reductionClin Pharmacol Ther201291110912222130116
   PubMed Web of Science ®Google Scholar
• CannonCPDanskyHMDavidsonMDEFINE investigatorsDesign of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapibAm Heart J20091584513519.e319781408
   PubMed Web of Science ®Google Scholar
• ChenFMaccubbinDYanLLipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemiaInt J Cardiol2012 Epub Feb 3.
   Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation2004110233512351715537681
   PubMed Web of Science ®Google Scholar
• VillinesTCStanekEJDevinePJThe ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment durationJ Am Coll Cardiol201055242721272620399059
   PubMed Web of Science ®Google Scholar
• YadavRFranceMYounisNExtended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safetyExpert Opin Pharmacother20121391345136222607011
   PubMed Web of Science ®Google Scholar
• University of OxfordTreatment of HDL to reduce the incidence of vascular events HPS2-THRIVEClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2007 [updated July 19, 2010]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00461630. NLM identifier: NCT00461630. Accessed July 5, 2012.
   Google Scholar
• University of WashingtonCarotid plaque characteristics by MRI in AIM-HIGH (Carotid MRI Substudy)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated June 19, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01178320. NLM identifier: NCT01178320. Accessed July 5, 2012.
   Google Scholar
• National Heart Lung, and Blood InstitutePlaque inflammation and dysfunctional hdl cholesterol in participants receiving niacin and statins in the AIM-HIGH Study (The HDL Proteomics Study)ClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2009 [updated February 23, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00880178. NLM identifier: NCT00880178. Accessed July 5, 2012.
   Google Scholar
• BuseJBRubinCJFrederichRMuraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetesClin Ther20052781181119516199244
   PubMed Web of Science ®Google Scholar
• GoldsteinBJRosenstockJAnzaloneDTouCOhmanKPEffect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trialCurr Med Res Opin200622122575259017166340
   PubMed Web of Science ®Google Scholar
• SaadMFGrecoSOseiKRagaglitazar Dose-Ranging Study GroupRagaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone armDiabetes Care20042761324132915161783
   PubMed Web of Science ®Google Scholar
• TardifJCGrégoireJL’AllierPLEffect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) InvestigatorsEffects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trialJAMA200797151675168217387133
   PubMed Web of Science ®Google Scholar
• WaksmanRTorgusonRKentKMA first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndromeJ Am Coll Cardiol201055242727273520538165
   PubMed Web of Science ®Google Scholar
• Cerenis TherapeuticsSAEffect of CER-001 on atherosclerosis in acute coronary syndrome (ACS) patients – efficacy and safety: the CHI SQUARE TrialClinicalTrialsgov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated June 14, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01201837. NLM identifier: NCT01201837. Accessed July 5, 2012.
   Google Scholar
• Resverlogix CorpNational Institute of Health ApoA-I synthesis stimulation and intravascular ultrasound for coronary atheroma regression evaluationClinicalTrials.gov [website on the Internet]Bethseda, MDUS National Library of Medicine2010 [updated June 27, 2012]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01067820. NLM identifier: NCT01067820. Accessed July 5, 2012.
   Google Scholar